Remibrutinib (LOU064)

remibrutinib · Novartis Pharmaceuticals

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Remibrutinib (LOU064), covering 2026-03-30 to 2026-03-30. Get the full timeline:

Most recent: Clinical Trial Update: Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria [Phase 2]

See pricing